Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2019-04-18
Target enrollment:
Participant gender:
Summary
A phase I study to evaluate safety of gemcitabine with nab-paclitaxel and concurrent IMRT for
locally advanced and borderline resectable pancreatic cancer. The goal of this study is to
evaluate if a chemotherapy regimen that provides superior systemic efficacy may be safely
delivered and enhance efficacy of tumor directed radiation therapy.